

# PHARMACY POLICY STATEMENT

## North Carolina Marketplace

**DRUG NAME**

**Xalkori (crizotinib)**

BENEFIT TYPE

## Lung Cancer or Lymphoma

Any request for cancer must be submitted through [NantHealth/Eviti](#) portal.

**CareSource considers Xalkori (crizotinib) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

DATE	ACTION/DESCRIPTION
09/28/2023	New policy for Xalkori created.

### References:

1. Xalkori [prescribing information]. Pfizer Inc.; 2023.
2. Schöffski P, Kubickova M, Wozniak A, et al. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. *Eur J Cancer*. 2021;156:12-23. doi:10.1016/j.ejca.2021.07.016
- 3.